Israel-based Teva Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE (glatiramer acetate injection) indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS).
CLICK ON TITLE BELOW
Teva secures FDA approval for new formulation of COPAXONE
88THBGU6YBFQ
No comments:
Post a Comment